Page last updated: 2024-11-13

unc 0638

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

UNC 0638: inhibits lysine methyltransferases G9a and GLP; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46224516
CHEMBL ID1231795
CHEBI ID95074
SCHEMBL ID14844528
MeSH IDM0561350

Synonyms (46)

Synonym
unc 0638
1255580-76-7
CHEMBL1231795 ,
NCGC00189220-01
2-cyclohexyl-6-methoxy-n-[1-(1-methylethyl)piperidin-4-yl]-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine
2-cyclohexyl-n-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine
unc0638 ,
bdbm50353128
NCGC00189220-05
unc-0638
unii-26a103l2fo
26a103l2fo ,
4-quinazolinamine, 2-cyclohexyl-6-methoxy-n-(1-(1-methylethyl)-4-piperidinyl)-7-(3-(1-pyrrolidinyl)propoxy)-
S8071
2-cyclohexyl-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine
gtpl7015
CCG-208706
HY-15273
CS-2035
smr004701318
MLS006010242
1255517-77-1
2-cyclohexyl-6-methoxy-n-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine
SCHEMBL14844528
2-cyclohexyl-n-(1-isopropyl-4-piperidinyl)-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine
AC-32711
AKOS024458105
DTXSID30154787
J-509244
2-cyclohexyl-6-methoxy-n-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine
CHEBI:95074
AS-74910
unc06381
NCGC00189220-03
BCP06142
EX-A2205
Q27089086
SB19045
HMS3426M09
HMS3743O07
4-quinazolinamine, 2-cyclohexyl-6-methoxy-n-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-
C72005
A920192
nsc764517
nsc-764517
2-cyclohexyl-n-(1-isopropyl-4-piperidyl)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" UNC0638 inhibition of G9a caused dosed accumulation of HbF up to 30% of total hemoglobin in differentiated cells."( Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR/γ-globin looping.
Byrnes, C; de Vasconcellos, JF; Dean, A; Kaushal, M; Krivega, I; Lee, YT; Miller, JL, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinazolinesAny organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency29.41070.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency6.50250.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
Interferon betaHomo sapiens (human)Potency29.41070.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA (cytosine-5)-methyltransferase 1Homo sapiens (human)IC50 (µMol)22.71880.01861.64886.0000AID1381131; AID1381133; AID1505769; AID1505820; AID1602431
Histone-lysine N-methyltransferase EHMT2Homo sapiens (human)IC50 (µMol)0.07670.00251.14809.2000AID1248877; AID1320623; AID1320661; AID1381130; AID1381132; AID1461884; AID1505768; AID1518756; AID1518831; AID1552780; AID1600063; AID1602418; AID1602447; AID618483; AID618490; AID618493; AID618496; AID618499; AID618502; AID618505; AID618508; AID700478; AID700479; AID700481; AID777197; AID777198
Histone-lysine N-methyltransferase EHMT2Homo sapiens (human)Ki0.00850.00370.14880.5700AID1320662; AID1868494; AID700481
Histone-lysine N-methyltransferase EHMT1Homo sapiens (human)IC50 (µMol)0.01750.01300.79954.9000AID1461885; AID1552779; AID1602448; AID700480
Spindlin-1Homo sapiens (human)IC50 (µMol)5.30003.20005.30007.4000AID1578932; AID1578933
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histone-lysine N-methyltransferase EHMT2Homo sapiens (human)Kd1.42000.13000.77501.4200AID1602419
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (74)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
DNA-templated transcriptionDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
positive regulation of gene expressionDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of gene expressionDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
methylationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
epigenetic programming of gene expressionDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
cellular response to amino acid stimulusDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
chromosomal DNA methylation maintenance following DNA replicationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
cellular response to bisphenol ADNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell apoptotic processDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switchingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to starvationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
regulation of DNA replicationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
synaptonemal complex assemblyHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
spermatid developmentHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
long-term memoryHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
fertilizationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
regulation of protein modification processHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
organ growthHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
phenotypic switchingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
response to ethanolHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
behavioral response to cocaineHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
oocyte developmentHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
neuron fate specificationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
response to fungicideHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to cocaineHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to xenobiotic stimulusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of autophagosome assemblyHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
peptidyl-lysine monomethylationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
regulation of embryonic developmentHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
response to fungicideHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
positive regulation of cold-induced thermogenesisHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
chromatin organizationSpindlin-1Homo sapiens (human)
gamete generationSpindlin-1Homo sapiens (human)
rRNA transcriptionSpindlin-1Homo sapiens (human)
Wnt signaling pathwaySpindlin-1Homo sapiens (human)
positive regulation of Wnt signaling pathwaySpindlin-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionSpindlin-1Homo sapiens (human)
meiotic cell cycleSpindlin-1Homo sapiens (human)
regulation of DNA-templated transcriptionSpindlin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
DNA bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
RNA bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
DNA (cytosine-5-)-methyltransferase activityDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
protein bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
zinc ion bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
methyl-CpG bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
DNA-methyltransferase activityDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
promoter-specific chromatin bindingDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
enzyme bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K9 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
C2H2 zinc finger domain bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K56 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K9me2 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
promoter-specific chromatin bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K9 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
C2H2 zinc finger domain bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K9me2 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein bindingSpindlin-1Homo sapiens (human)
methylated histone bindingSpindlin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
female germ cell nucleusDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
nucleusDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
nucleoplasmDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
replication forkDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
pericentric heterochromatinDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
nucleusDNA (cytosine-5)-methyltransferase 1Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nuclear speckHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nuclear bodyHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleusSpindlin-1Homo sapiens (human)
nucleoplasmSpindlin-1Homo sapiens (human)
nucleolusSpindlin-1Homo sapiens (human)
spindleSpindlin-1Homo sapiens (human)
cytosolSpindlin-1Homo sapiens (human)
nuclear membraneSpindlin-1Homo sapiens (human)
cytosolSpindlin-1Homo sapiens (human)
nucleoplasmSpindlin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (173)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID618501Ratio of EC50 for human 22Rv1 cells to IC50 for G9a in human 22Rv1 cells2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1868527Antiproliferative activity against human Rh30 cells assessed as inhibition of cell growth incubated for 144 hrs2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1602448Inhibition of GLP (unknown origin)2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID1530568Cytotoxicity against HFF2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID1505768Inhibition of human G9a using biotinylated-H3K9 peptide as substrate after 1 hr in presence of SAM by TR-FRET assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
AID1530564Antiplasmodial activity against Plasmodium falciparum Dd2 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation measured after 48 hrs by microbeta liquid scintillation counting method2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID1868547Antiproliferative activity against human RD cells assessed as reduction in live cells at 3.5 uM incubated for 72 hrs by calceinAM/propidium iodide staining based fluorescence microscopy2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1552781Selectivity ratio of IC50 for N-terminal GST tagged human recombinant EHMT2 (785 to 1210 residues) expressed in baculovirus infected Sf9 insect cells to IC50 for N-terminal GST tagged human recombinant EHMT1 (794 to 1294 residues) expressed in baculovirus2019Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17
Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2.
AID777190AUC (0 to 24 hrs) in Swiss albino mouse plasma at 5 mg/kg, ip2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
AID1518756Inhibition of human G9a using core histone H3 as substrate incubated for 1 hr in presence of [3H]-SAM by filter binding method2019European journal of medicinal chemistry, Dec-15, Volume: 184Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID618498Ratio of EC50 for human PC3 cells to IC50 for G9a in human PC3 cells2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID700478Inhibition of G9a in human MCF7 cells after 48 hrs by clonogenic assay2012European journal of medicinal chemistry, Oct, Volume: 56Oncoepigenomics: making histone lysine methylation count.
AID618485Inhibition of G9a expressed in H1299 cells assessed as inhibition of dimethylation of p53 at lys 373 at 0.25 uM after 24 hrs by Western blot analysis2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1845920Reactivation of HIV-1 latency infected in human Th17 cells assessed as increase in HIV production by measuring phosphorylated S175 CDK9 levels at 1 uM incubated for 96 hrs by flow cytometry2021European journal of medicinal chemistry, Mar-05, Volume: 213HIV latency reversal agents: A potential path for functional cure?
AID618563Cytotoxicity against human IMR90 cells assessed as cell viability after 48 hrs by MTT assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID618492Ratio of EC50 for human MDA-MB-231 cells to IC50 for G9a in human MDA-MB-231 cells2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1320622Inhibition of G9a (unknown origin) at 10 uM using biotinylated-histone H3 (1 to 21 residues)/S-adenosyl-methionine as substrate/methyl donor after 3 hrs by AlphaScreen assay relative to control2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
AID1065216Effect on total H3K27Me3 protein level in human PC3 cells at 0.01 to 10 uM after 72 hrs by Western blotting analysis2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.
AID1530567Selectivity index, ratio of IC50 for asynchronous form of Plasmodium falciparum 3D7 infected in human erythrocytes to IC50 for mouse spleen cells2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID1868514Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth at 0.2 to 2.5 uM incubated for 72 to 144 hrs by trypan blue staining based analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1530566Cytotoxicity against mouse spleen cells2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID1602419Binding affinity to human His-tagged G9a expressed in Escherichia coli Rosetta (DE3) after 30 mins by MST binding assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID777193Half life in mouse liver microsomes2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
AID1602437Metabolic stability in human liver microsomes assessed as parent compound turn over percentage at 1 mM preincubated for 5 mins followed by NADPH addition and measured for 60 mins by UHPLC analysis2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID1461884Inhibition of EHMT2 (unknown origin)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Cycloalkane analogues of sinefungin as EHMT1/2 inhibitors.
AID618486Inhibition of GLP expressed in H1299 cells assessed as inhibition of dimethylation of p53 at lys 373 at 0.25 uM after 24 hrs by Western blot analysis2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID618493Inhibition of G9a in human MCF7 cells assessed as reduction of H3K9me2 after 48 hrs by In-Cell Western assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1552780Inhibition of N-terminal GST tagged human recombinant EHMT2 (785 to 1210 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in conversion of SAH to AMP using histone H3 as substrate and SAH as cosubstrate incubated for 30 m2019Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17
Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2.
AID1320624Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
AID1602422Binding affinity to human His-tagged G9a expressed in Escherichia coli Rosetta (DE3) assessed as equilibrium dissociation constant by SPR assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID1320661Inhibition of G9a (unknown origin) using histone H3 (1 to 25 residues) as substrate preincubated for 2 mins followed by substrate addition measured for 20 mins by SAHH-coupled assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
AID1868523Antiproliferative activity against human RD cells assessed as inhibition of cell growth incubated for 72 hrs2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID618503Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1602447Inhibition G9a (unknown origin)2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID618505Inhibition of G9a in p53-deficient human HCT116 cells assessed as reduction of H3K9me2 after 48 hrs by In-Cell Western assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID618489Effect on total p53 levels in human H1299 cells at 0.25 uM after 24 hrs by Western blot analysis2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID777194Intrinsic clearance in mouse liver microsomes2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
AID1602438Apparent permeability of the compound after 24 hrs by PAMPA2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID1505820Inhibition of DNMT1 (unknown origin) by radioactive methyl transfer assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
AID1530562Antiplasmodial activity against asynchronous form of Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition at 10 uM after 48 hrs by SYBR green1 staining based flow cytometry relative to control2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID1065215Effect on total H3K36Me2 protein level in human PC3 cells at 0.01 to 10 uM after 72 hrs by Western blotting analysis2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.
AID1602420Binding affinity to human His-tagged G9a expressed in Escherichia coli Rosetta (DE3) assessed as association rate constant after 60 secs by SPR assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID618504Ratio of EC50 for human HCT116 cells to IC50 for G9a in human HCT116 cells2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1461885Inhibition of EHMT1 (unknown origin)2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Cycloalkane analogues of sinefungin as EHMT1/2 inhibitors.
AID618500Cytotoxicity against human 22Rv1 cells assessed as cell viability after 48 hrs by MTT assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1320625Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
AID1327005Inhibition of His-sumo-tagged BALB/c mouse thymus histone methyltransferase G9a (969 to 1263 residues) using biotin labeled peptide substrate at 10 uM after 30 mins in presence of [methyl-3H]-SAM by microbeta scintillation counting relative to control2016European journal of medicinal chemistry, Oct-21, Volume: 122Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.
AID1868494Inhibition of G9a (unknown origin) assessed as reduction in substrate methylation using histone H3 and SAM as substrate measured after 15 to 60 mins by microfluidic capillary electrophoresis analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1868542Antiproliferative activity against human Rh30 cells assessed as reduction in live cells at 3.5 uM incubated for 24 hrs by calceinAM/propidium iodide staining based fluorescence microscopy2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1602418Inhibition of recombinant human G9a using biotinylated-Histone H3 peptide (1 to 21 residues) after 30 mins in presence of SAM by AlphaLISA assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID618490Inhibition of G9a in human MDA-MB-231 cells assessed as reduction of H3K9me2 after 48 hrs by In-Cell Western assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1530563Antiplasmodial activity against asynchronous form of Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition after 48 hrs by SYBR green1 staining based flow cytometry2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID700476Inhibition of adrenergic alpha1A receptor at 1 uM2012European journal of medicinal chemistry, Oct, Volume: 56Oncoepigenomics: making histone lysine methylation count.
AID1868554Induction of apoptosis in human Rh30 cells assessed as increase in caspase 3/7 level at 3.5 uM incubated for 24 hrs2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1602431Inhibition of N-terminal GST-tagged recombinant full length human DNMT1 (2 to 1632 residues) using poly(dI-dC)):poly(dI-dC) as substrate preincubated for 20 mins followed by [3H]-SAM and measured after 60 mins by scintillation counting2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID618499Inhibition of G9a in human 22Rv1 cells assessed as reduction of H3K9me2 after 48 hrs by In-Cell Western assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1381131Inhibition of human DNMT1 using polydeoxyinosine polydeoxycytosine DNA as substrate after 15 mins in presence of SAM by TR-FRET assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
AID618488Effect on total GLP level in human H1299 cells at 0.25 uM after 24 hrs by Western blot analysis2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID618494Cytotoxicity against human MCF cells assessed as cell viability after 48 hrs by MTT assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID618495Ratio of EC50 for human MCF cells to IC50 for G9a in human MCF cells2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID618502Inhibition of G9a in human HCT116 cells assessed as reduction of H3K9me2 after 48 hrs by In-Cell Western assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1600063Inhibition G9a (unknown origin)2019European journal of medicinal chemistry, Oct-01, Volume: 179Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
AID1868508Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID777198Inhibition of lysine methyltransferase G9a (unknown origin) using [3H]-SAM as substrate after 0.25 hrs by scintillation proximity assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
AID1374902Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1505769Inhibition of human DNMT1 using polydeoxyinosine polydeoxycytosine DNA as substrate after 15 mins in presence of SAM by TR-FRET assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
AID1374901Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID618487Effect on total G9a level in human H1299 cells at 0.25 uM after 24 hrs by Western blot analysis2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID618564Ratio of EC50 for human IMR90 cells to IC50 for G9a in human IMR90 cells2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1381130Inhibition of human G9a using biotinylated-H3K9 peptide as substrate after 1 hr in presence of SAM by TR-FRET assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
AID1722381Inhibition of G9a methyltransferase activity in human CD34+ cells assessed as induction of fetal type gamma globin at 1 uM in presence of erythropoietin measured after 21 days by staining based method2020Bioorganic & medicinal chemistry letters, 10-15, Volume: 30, Issue:20
Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.
AID1327006Inhibition of histone methyltransferase G9a (unknown origin) assessed as growth inhibition of cells at 10 uM after 48 hrs by cell based CCK8 assay relative to control2016European journal of medicinal chemistry, Oct-21, Volume: 122Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.
AID1602439Apparent permeability of the compound after 24 hrs by BBB-PAMPA2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID700477Inhibition of muscarinic M2 receptor at 1 uM2012European journal of medicinal chemistry, Oct, Volume: 56Oncoepigenomics: making histone lysine methylation count.
AID1552779Inhibition of N-terminal GST tagged human recombinant EHMT1 (794 to 1294 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in conversion of SAH to AMP using histone H3 as substrate and SAH as cosubstrate incubated for 30 m2019Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17
Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2.
AID1065217Effect on total histone 3 protein level in human PC3 cells at 0.01 to 10 uM after 72 hrs by Western blotting analysis2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.
AID618497Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1602427Inhibition of recombinant human SETD8 at 10 uM using biotinylated-Histone H4 peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins in presence of SAM by AlphaLISA assay relative to control2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID700475Inhibition of adrenergic alpha1B receptor at 1 uM2012European journal of medicinal chemistry, Oct, Volume: 56Oncoepigenomics: making histone lysine methylation count.
AID618506Cytotoxicity against p53-deficient human HCT116 cells assessed as cell viability after 48 hrs by MTT assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1518831Inhibition of G9a (unknown origin)2019European journal of medicinal chemistry, Dec-15, Volume: 184Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
AID700479Inhibition of G9a in human MDA-MB-231 cells after 48 hrs by clonogenic assay2012European journal of medicinal chemistry, Oct, Volume: 56Oncoepigenomics: making histone lysine methylation count.
AID618483Inhibition of G9a assessed as hydrolysis of S-adenosyl-L-homocysteine after 2 mins by SAHH-coupled fluorescence assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1381133Inhibition of DNMT1 (unknown origin)2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
AID1845919Reactivation of HIV-1 latency infected in human Th17 cells assessed as increase in HIV production by measuring phosphorylated S175 CDK9 levels at 10 nM incubated for 96 hrs by flow cytometry2021European journal of medicinal chemistry, Mar-05, Volume: 213HIV latency reversal agents: A potential path for functional cure?
AID1530569Selectivity index, ratio of IC50 for asynchronous form of Plasmodium falciparum 3D7 infected in human erythrocytes to IC50 for HFF2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID700481Competitive inhibition of G9a by fluorescence polarization assay in presence of fluorescein-labeled H3 peptide2012European journal of medicinal chemistry, Oct, Volume: 56Oncoepigenomics: making histone lysine methylation count.
AID700480Competitive inhibition of GLP by fluorescence polarization assay in presence of fluorescein-labeled H3 peptide2012European journal of medicinal chemistry, Oct, Volume: 56Oncoepigenomics: making histone lysine methylation count.
AID618491Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by MTT assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1065218Inhibition of G9a in human PC3 cells assessed as reduction in H3K9Me2 level at 3 uM after 72 hrs by Western blotting analysis relative to control2014ACS medicinal chemistry letters, Feb-13, Volume: 5, Issue:2
Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.
AID1868526Antiproliferative activity against human Rh30 cells assessed as inhibition of cell growth incubated for 72 hrs2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1381132Inhibition of G9a (unknown origin)2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
AID1868525Antiproliferative activity against human Rh30 cells assessed as inhibition of cell growth incubated for 24 hrs2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1868509Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 144 hrs by CellTiter-Glo luminescent cell viability assay2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1578933Inhibition of biotin-H3(1-23)K4me3 binding to recombinant human C-terminal His6-tagged SPIN1 (49 to 262 residues) expressed in Escherichia coli BL21 (DE3) cells incubated for 90 mins by AlphaLISA assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1).
AID1327004Inhibition of His-sumo-tagged BALB/c mouse thymus histone methyltransferase G9a (969 to 1263 residues) catalytic domain expressed in Escherichia coli BL21 (DE3) assessed as response unit at 10 to 100 uM by SPR assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.
AID1320662Competitive inhibition of G9a (unknown origin) by Morrison plot analysis in presence of histone H3 (1 to 25 residues)2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
AID618507Ratio of EC50 for p53-deficient human HCT116 cells to IC50 for G9a in p53-deficient human HCT116 cells2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1868522Antiproliferative activity against human RD cells assessed as inhibition of cell growth incubated for 24 hrs2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1868519Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1530565Antiplasmodial activity against asynchronous form of Plasmodium falciparum W2 infected in human erythrocytes assessed as parasite growth inhibition after 48 hrs by SYBR green1 staining based flow cytometry2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID618508Inhibition of G9a in human IMR90 cells assessed as reduction of H3K9me2 after 48 hrs by In-Cell Western assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1552782Inhibition of EHMT1/2 in human AsPC1 cells assessed as H3K9Me2 level at 10 uM incubated for 48 hrs by Western blot analysis relative to control2019Bioorganic & medicinal chemistry letters, 09-01, Volume: 29, Issue:17
Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2.
AID1868507Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID777191Cmax in Swiss albino mouse plasma at 5 mg/kg, ip2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
AID777195Ratio of EC50 for human MDA-MB-231 cells to IC50 for lysine methyltransferase G9a in human MDA-MB-231 cells2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
AID777197Inhibition of lysine methyltransferase G9a in human MDA-MB-231 cells assessed as reduction of H3K9me2 cellular level by immunofluorescence in-cell Western assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
AID1320623Inhibition of G9a (unknown origin) using biotinylated-histone H3 (1 to 21 residues)/S-adenosyl-methionine as substrate/methyl donor after 3 hrs by AlphaScreen assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
AID1248877Inhibition of G9a (unknown origin) using [histone H3 1 to 25 residues] and SAM substrate by scintillation proximity assay2014MedChemComm, Dec-19, Volume: 5, Issue:12
Identification of 2,4-diamino-6,7-dimethoxyquinoline derivatives as G9a inhibitors†Electronic supplementary information (ESI) available. See DOI: 10.1039/c4md00274a.
AID1602421Binding affinity to human His-tagged G9a expressed in Escherichia coli Rosetta (DE3) assessed as dissociation rate constant after 100 secs by SPR assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID1602428Inhibition of recombinant human SETD8 at 25 uM using biotinylated-Histone H4 peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins in presence of SAM by AlphaLISA assay relative to control2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
AID777196Cytotoxicity against human MDA-MB-231 cells after 48 hrs by Alamar Blue assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
AID1320626Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
AID618496Inhibition of G9a in human PC3 cells assessed as reduction of H3K9me2 after 48 hrs by In-Cell Western assay2011Journal of medicinal chemistry, Sep-08, Volume: 54, Issue:17
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
AID1868524Antiproliferative activity against human RD cells assessed as inhibition of cell growth incubated for 144 hrs2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1578932Inhibition of FL-H3K4me3 binding to recombinant human C-terminal His6-tagged SPIN1 (49 to 262 residues) expressed in Escherichia coli BL21 (DE3) cells incubated for 30 mins by fluorescence polarization displacement assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1).
AID1346126Human euchromatic histone lysine methyltransferase 2 (2.1.1.43 Histone methyltransferases (HMTs))2011Nature chemical biology, Jul-10, Volume: 7, Issue:8
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells.
AID1346083Human euchromatic histone lysine methyltransferase 1 (2.1.1.43 Histone methyltransferases (HMTs))2011Nature chemical biology, Jul-10, Volume: 7, Issue:8
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's38 (73.08)24.3611
2020's14 (26.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.23 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (7.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (92.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]